- Home
- AARD vs NODK Comparison
AARD vs NODK Comparison
Compare AARD & NODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- NODK
- Stock Information
- Founded
- AARD 2017
- NODK 1946
- Country
- AARD United States
- NODK United States
- Employees
- AARD N/A
- NODK N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- NODK Property-Casualty Insurers
- Sector
- AARD Health Care
- NODK Finance
- Exchange
- AARD Nasdaq
- NODK Nasdaq
- Market Cap
- AARD 271.1M
- NODK 265.4M
- IPO Year
- AARD 2025
- NODK 2017
- Fundamental
- Price
- AARD $11.50
- NODK $12.92
- Analyst Decision
- AARD Strong Buy
- NODK
- Analyst Count
- AARD 5
- NODK 0
- Target Price
- AARD $33.00
- NODK N/A
- AVG Volume (30 Days)
- AARD 37.2K
- NODK 11.4K
- Earning Date
- AARD 08-18-2025
- NODK 08-08-2025
- Dividend Yield
- AARD N/A
- NODK N/A
- EPS Growth
- AARD N/A
- NODK N/A
- EPS
- AARD N/A
- NODK 0.07
- Revenue
- AARD N/A
- NODK $310,389,000.00
- Revenue This Year
- AARD N/A
- NODK N/A
- Revenue Next Year
- AARD N/A
- NODK N/A
- P/E Ratio
- AARD N/A
- NODK $184.84
- Revenue Growth
- AARD N/A
- NODK N/A
- 52 Week Low
- AARD $4.88
- NODK $12.01
- 52 Week High
- AARD $19.58
- NODK $17.24
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- NODK 51.92
- Support Level
- AARD N/A
- NODK $12.67
- Resistance Level
- AARD N/A
- NODK $13.49
- Average True Range (ATR)
- AARD 0.00
- NODK 0.40
- MACD
- AARD 0.00
- NODK -0.01
- Stochastic Oscillator
- AARD 0.00
- NODK 53.85
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.